| Document |
Document Title |
|
WO/2021/017071A1 |
Disclosed in the present application are an antibody or an antigen-binding portion thereof binding to human ST2, a polynucleotide encoding the antibody or the antigen-binding portion thereof, a vector containing the polynucleotide, a hos...
|
|
WO/2021/012721A1 |
Disclosed in the present invention are a naphthalenesulfonamide compound, a preparation method, and an application. The naphthalenesulfonamide compound provided by the present invention can interfere with Keap1-Nrf2 binding and activate ...
|
|
WO/2021/013771A1 |
The invention relates to the use of ferroportin inhibitor compounds of the general formula (I) for treating transfusion-dependent β-thalassemia.
|
|
WO/2021/012018A1 |
The disclosure relates to heterocyclic compounds and methods for their preparation. The disclosure provides compounds that may have beneficial therapeutic activity in the treatment of a disease or condition mediated by excessive or other...
|
|
WO/2021/014420A1 |
The invention relates to the use of sotagliflozin in patients with type 2 diabetes mellitus and moderate renal impairment.
|
|
WO/2021/012717A1 |
Disclosed are a compound as represented by general formula (I) or a pharmaceutically acceptable salt thereof, and a preparation method therefor. Also disclosed are a pharmaceutical composition containing the compound and the use of the c...
|
|
WO/2021/013772A1 |
The invention relates to the use of ferroportin inhibitor compounds of the general formula (I) for preventing and treating kidney injuries, such as in particular acute kidney injuries, and the symptoms and pathological conditions associa...
|
|
WO/2021/009525A1 |
The present invention relates to novel medicinal and/or pharmaceutical compositions indicated as composition A and composition B in liquid form for use as a medicinal composition or medicament for intravesical instillation, in the simult...
|
|
WO/2021/010824A1 |
The current invention relates to use of oral disodium pyrophosphate for preventing and/or reducing tissue calcification, particularly soft tissue calcification, and/or diseases or disorders characterized by low plasma PPi levels, as, e.g...
|
|
WO/2021/009197A1 |
Disclosed herein are pharmaceutical formulations comprising verinurad or a pharmaceutically acceptable salt thereof that are resistant to alcohol-induced dose dumping and may be used in therapeutic and/or prophylactic methods.
|
|
WO/2021/004910A1 |
The present invention relates to methods for treating bacterial infections caused by or associated with Mycoplasma genitalium, which comprises administration of gepotidacin or pharmaceutically acceptable salts thereof, and doxycycline to...
|
|
WO/2021/004494A1 |
Provided are an anti-C5 humanized monoclonal antibody having a low immunogenicity and a low ADCC/CDC function, and the use thereof. By means of modifying the amino acid sequence in the framework region of an Eculizumab monoclonal antibod...
|
|
WO/2021/006941A1 |
The present invention relates to telmisartan or a pharmaceutically acceptable salt thereof as a medicament for the treatment of elevated urinary protein-to-creatinine ratio (UPC) levels in dogs, wherein the therapeutically effective amou...
|
|
WO/2021/004549A1 |
The present invention relates to the field of using a dual target vascular inhibitor to treat fibrosis diseases. More specifically, provided is a use for a dual target vascular inhibitor in preparing drugs for preventing or treating fibr...
|
|
WO/2021/004922A1 |
Compositions consist essentially of trigonelline or consist of trigonelline. The compositions can be used in food or beverage applications, pharmaceutical formulations, or as a dietary supplement. The compositions can be administered to ...
|
|
WO/2021/002481A1 |
The purpose of the present invention is to provide a drug delivery carrier which can be accumulated selectively in the kidney in vivo and which can show high biodegrability and drug-release capability in the kidney. The present invention...
|
|
WO/2021/000933A1 |
Provided are a class of compounds with pyrimidinone structure as chymase inhibitor drugs, the compound represented by formula (I), the pharmaceutically acceptable salts and isomers thereof, and the pharmaceutical compositions containing ...
|
|
WO/2020/222139A9 |
Polymeric liquid formulations for instillation into the bladder or kidney for prolonged release of an active agent and methods of treatment using the formulations are described. When in contact with urine, the formulation forms a mass in...
|
|
WO/2021/002359A1 |
The present inventors have identified antisense oligonucleotides (ASOs) which act on a p53 gene transcription product. By using these relatively short oligonucleotides, the amount of p53 mRNA can be reduced and the expression of the prot...
|
|
WO/2021/000584A1 |
Provided is a thrombin binding circular aptamer, and the nucleotide sequence thereof is selected from at least one of a)-d): a) a nucleotide sequence as shown in SEQ ID NO:1, wherein the 5' end and 3' end are connected into a ring; b) a ...
|
|
WO/2021/002588A1 |
The present invention provides a pharmaceutical composition containing tamsulosin or hydrochloride thereof, which can be applied to an oral preparation, and a preparation method therefor, wherein when the composition is formed into an en...
|
|
WO/2021/000018A1 |
The invention relates to anti-PSMA antibodies comprising a heavy chain constant region comprising one or more amino acid substitutions compared to a wild-type IgG, wherein the one or more amino acid substitutions reduce the affinity of t...
|
|
WO/2021/000017A1 |
The invention relates to anti-CAIX antibodies comprising a heavy chain constant region comprising one or more amino acid substitutions compared to a wild-type IgG, wherein the one or more amino acid substitutions reduce the affinity of t...
|
|
WO/2020/262983A1 |
The present invention relates to a pharmaceutical composition comprising an inhibitor against the expression or activation of novel ADP-ribosyl cyclase or a naturally occurring mutant thereof as an active ingredient for preventing or tre...
|
|
WO/2020/262603A1 |
The purpose of the present invention is to provide a drug for the prevention and/or treatment of a disease associated with the activation of an EP2 receptor, the drug containing, as an active ingredient, a compound having an antagonistic...
|
|
WO/2020/260463A1 |
The present invention covers P2X3 inhibitor compounds of general formula (I) in which R1 and R2 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compos...
|
|
WO/2020/264065A1 |
The present invention relates to new anti-angiopoietin 2 (ANGPT2) neutralizing antibodies for therapeutic and diagnostic methods and composition using them.
|
|
WO/2020/262184A1 |
Provided is a novel method for inhibiting myostatin. An antisense oligonucleotide having a base length of 15-30 that has a base sequence complementary to the target site of exon 1 of myostatin gene, a salt thereof or a solvate of the s...
|
|
WO/2020/260356A1 |
The invention relates to bacteria of the Christensenellaceae family and compositions containing same for their use in the prevention and/or treatment of renal insufficiency in humans or animals.
|
|
WO/2020/262114A1 |
The purpose of the present invention is to provide a pharmaceutical agent which activates mitochondrial function, particularly, an inexpensive pharmaceutical agent. The problem can be solved by a mitochondrial function activator of the...
|
|
WO/2020/256795A1 |
The present disclosure relates to methods of treating neointimal hyperplasia. The methods include selecting a subject having a blood vessel abnormality, and administering to the subject an amount of a composition, wherein the composition...
|
|
WO/2020/257248A1 |
This document provides methods and materials related to the treatment of a lung condition, such as chronic obstructive pulmonary disease (COPD), using a composition containing live Prevotella (e.g., P. histicola and/or P. melaninogenica)...
|
|
WO/2020/256905A1 |
Compositions for and methods of treating liver injury are provided. Said compositions comprise MG53 or express MG53. Said compositions can be used for treating chronic or acute injured liver tissue and can be administered systemically, l...
|
|
WO/2020/257281A1 |
Methods and compositions relating to isolated mitochondria are disclosed. For example, cells, tissues, or organs can be treated with isolated mitochondria, such as porcine mitochondria, to improve mitochondrial function in the cell, tiss...
|
|
WO/2020/254369A1 |
Disclosed herein are new O-biphenyl- and O-phenylheteroaryl- mannoside compounds and compositions and their application as pharmaceuticals for use in the treatment of human disease. Methods of inhibition of FimH activity in human subject...
|
|
WO/2020/257139A1 |
The present invention provides compounds of Formula (I): (I), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA recepto...
|
|
WO/2020/257171A1 |
The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kid...
|
|
WO/2020/256309A1 |
The present invention relates to a controlled-release composition for oral administration and a method for preparing same, the composition comprising a complex of: a hydrophilic alpha adrenergic blocker compound or a salt thereof; and cl...
|
|
WO/2020/255464A1 |
Provided is a novel preventive agent or therapeutic agent for renal disorders. This preventive agent or therapeutic agent for renal disorders contains a thioredoxin derivative as an active ingredient.
|
|
WO/2020/257138A1 |
The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhi...
|
|
WO/2020/257135A1 |
The present invention provides compounds of Formula (I), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inh...
|
|
WO/2020/257720A1 |
The present invention provides method of treating diseases, disorders and conditions in a human subject comprising administering to the subject a population of exosomes or a composition comprising a population of exosomes, wherein said p...
|
|
WO/2020/253659A1 |
Provided are certain URAT1 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2020/250223A1 |
The invention relates to a novel substituted amino acids, agricultural compositions comprising the novel substituted amino acids, and their use for controlling undesired plant growth alone or in combination with crop protection agents su...
|
|
WO/2020/249710A1 |
Methods of treating and preventing fibrosis and pathological inflammation through inhibition of WWP2 are disclosed, as well as agents for use in such methods.
|
|
WO/2020/248327A1 |
Disclosed are a fatty acid synthase inhibitor and the use thereof, with same belonging to the field of medical biotechnology. The fatty acid synthase inhibitor can significantly inhibit the activity of a fatty acid synthase without affec...
|
|
WO/2020/252129A1 |
Provided are methods for treatment of Fabry disease in a patient having renal impairment. Certain methods comprise administering to the patient about 100 mg to about 300 mg free base equivalent of migalastat or salt thereof at a frequenc...
|
|
WO/2020/248776A1 |
Provided is the use of an Abelmoschi corolla extract in the preparation of a drug for treating fibrosis, wherein the extract contains at least 15% of gossypetin-3-O-β-D-glucose-8-O-β-D-glucuronide, with same being prepared by means of ...
|
|
WO/2020/251020A1 |
The present invention addresses the problem of providing a cell population including mesenchymal cells, capable of forming a cell sheet that can be spontaneously peeled off from a substrate. The present invention relates to a cell popula...
|
|
WO/2020/249139A1 |
Disclosed in the present invention are a potassium salt crystal form B of a phosphodiesterase type 5 inhibitor, and a preparation method and a use therefor. The structural formula of the phosphodiesterase type 5 inhibitor is as shown in ...
|
